Antibody Responses and Avidity of Naturally Acquired Anti-Plasmodium vivax Duffy Binding Protein (PvDBP) Antibodies in Individuals from an Area with Unstable Malaria Transmission
- 1 June 2011
- journal article
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 84 (6), 944-950
- https://doi.org/10.4269/ajtmh.2011.11-0001
Abstract
Plasmodium vivax remains an important cause of morbidity outside Africa, and no effective vaccine is available against this parasite. The P. vivax Duffy binding protein (PvDBP) is essential during merozoite invasion into erythrocytes, and it is a target for protective immunity against malaria. This investigation was designed to evaluate naturally acquired antibodies to two variant forms of PvDBP-II antigen (DBP-I and -VI) in malaria individuals (N = 85; median = 22 years) who were living in hypoendemic areas in Iran. The two PvDBP-II variants were expressed in Escherichia coli, and immunoglobulin G (IgG) isotype composition and avidity of naturally acquired antibodies to these antigens were measured using enzyme-linked immunosorbent assay (ELISA). Results showed that almost 32% of the studied individuals had positive antibody responses to the two PvDBP-II variants, and the prevalence of responders did not differ significantly (P > 0.05; χ(2) test). The IgG-positive samples exhibited 37.03% and 40.8% high-avidity antibodies for PvDBP-I and PvDBP-VI variants, respectively. Furthermore, high-avidity IgG1 antibody was found in 39.1% of positive sera for each examined variant antigen. The avidity of antibodies for both PvDBP variant antigens and the prevalence of responders with high- and intermediate-avidity IgG, IgG1, and IgG3 antibodies were similar in patients (P > 0.05; χ(2) test). Moreover, the prevalence of IgG antibody responses to the two variants significantly increased with exposure and host age. To sum up, the results provided additional data in our understanding of blood-stage immunity to PvDBP, supporting the rational development of an effective blood-stage vaccine based on this antigen.Keywords
This publication has 44 references indexed in Scilit:
- Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy peopleProceedings of the National Academy of Sciences of the United States of America, 2010
- Naturally Acquired Antibodies to Plasmodium vivax Duffy Binding Protein (DBP) in Rural Brazilian AmazonThe American Journal of Tropical Medicine and Hygiene, 2010
- Strain-Specific Duffy Binding Protein Antibodies Correlate with Protection against Infection with Homologous Compared to Heterologous Plasmodium vivax Strains in Papua New Guinean ChildrenInfection and Immunity, 2009
- Naturally acquired inhibitory antibodies toPlasmodium vivaxDuffy binding protein are short-lived and allele-specific following a single malaria infectionClinical and Experimental Immunology, 2009
- Multidrug-Resistant Plasmodium vivax Associated with Severe and Fatal Malaria: A Prospective Study in Papua, IndonesiaPLoS Medicine, 2008
- Plasmodium vivax and Mixed Infections Are Associated with Severe Malaria in Children: A Prospective Cohort Study from Papua New GuineaPLoS Medicine, 2008
- Plasmodium vivax Invasion of Human Erythrocytes Inhibited by Antibodies Directed against the Duffy Binding ProteinPLoS Medicine, 2007
- Invasion of Red Blood Cells by Malaria ParasitesCell, 2006
- Genetic polymorphism of the Duffy receptor binding domain of Plasmodium vivax in Colombian wild isolatesMolecular and Biochemical Parasitology, 1996
- The duffy receptor family of plasmodium knowlesi is located within the micronemes of invasive malaria merozoitesCell, 1990